Floatz logo

Mirdametinib

Neurofibromatosis 1 (NF1)

University of Alabama at BirminghamSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Neurofibromatosis 1 (NF1) cohort.

Asset / SponsorPhaseRating
gsk1120212
Novartis Pharmaceuticals
Phase 4B
Dabrafenib
Novartis Pharmaceuticals
Phase 4B
Anti-Thymoglobulin, Rabbit
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2CCC

View all 14 →

Same molecule, other indications

Mirdametinib is also rated in:

melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →